Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 29, 2008 (Second Quarter of Fiscal 2008)
Business Overview: Illumina is a leading developer of integrated systems for large-scale genetic analysis, serving research, pharmaceutical, and biotechnology markets. The company operates primarily in one segment, focusing on genotyping, gene expression, and DNA sequencing technologies (including BeadArray and Solexa-derived Sequencing-by-Synthesis).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 29, 2008 |
Six Months Ended June 29, 2008 |
Six Months Ended July 1, 2007 |
|---|---|---|---|
| Total Revenue | $140,177 | $262,038 | $156,685 |
| Net Income (Loss) | $15,398 | $28,826 | $(288,812) |
| Diluted EPS | $0.23 | $0.44 | $(5.39) |
| Operating Cash Flow | N/A | $(25,532) | $39,126 |
| Cash & Equivalents (End of Period) | $132,968 | $132,968 | $81,117 |
| Total Debt (Current Portion) | $400,000 | $400,000 | $16 |
Note: The prior year six-month period included a one-time $303.4 million charge for acquired in-process research and development (IPR&D) related to the Solexa acquisition, resulting in a significant net loss.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 66% year-over-year for the quarter and 67% for the six-month period. Product revenue grew 73% (quarter) and 76% (six months), driven by strong demand for Infinium consumables and the Genome Analyzer II (GAII) instrument.
- Profitability: The company returned to profitability, reporting net income of $15.4 million for the quarter compared to $9.3 million in the prior year quarter. This contrasts sharply with the prior year six-month net loss of $288.8 million, which was heavily impacted by the non-cash IPR&D charge from the Solexa acquisition.
- Expense Increases:
- R&D: Increased 29% year-over-year due to personnel costs and development of new sequencing and BeadArray products.
- SG&A: Increased 53% year-over-year, driven by sales force expansion, international growth, and higher stock-based compensation.
- Amortization: Increased significantly (303% for the quarter) due to the amortization of a $36 million intangible asset recorded from the Affymetrix litigation settlement.
- Debt Reclassification: The $400 million Convertible Senior Notes were reclassified from long-term to current liabilities because the notes became convertible during the period (April 1 through September 30, 2008).
Guidance, Outlook, Risks, and Unusual Items
- Convertible Notes Liquidity Risk: The $400 million Convertible Senior Notes are currently convertible. Management states they do not have sufficient cash to pay the full principal amount if all notes were converted immediately. However, they do not expect conversion as the notes trade above their conversion value. If conversion occurs, the company may need to seek additional financing.
- Investment Portfolio Illiquidity: Approximately $55.9 million of the company's investments are in auction rate securities. Due to market failures, these are illiquid and have been reclassified as long-term investments. An unrealized loss of $3.1 million was recorded, deemed temporary.
- Legal Settlements: A $90 million payment was made to Affymetrix in January 2008 to settle patent litigation. $36 million was capitalized as an intangible asset (licensed technology) and is being amortized; the remainder was expensed in the prior year.
- Acquisition: Subsequent to the period end (July 22, 2008), Illumina announced the acquisition of Avantome, Inc. for $25 million upfront plus up to $35 million in contingent consideration.
- Outlook: Management expects revenue to continue increasing due to new product launches (Human1M-Duo, HumanHT-12, iScan System) and growth in the installed base. Capital expenditures for 2008 are anticipated to be approximately $55.1 million.
Key Facts for Investor Verification
- Debt Conversion Status: Verify the trading price of the $400 million Convertible Senior Notes relative to the conversion price to assess the likelihood of conversion and potential cash outflow.
- Auction Rate Securities: Monitor the liquidity status of the $55.9 million in auction rate securities and any potential future impairment charges if the market does not recover.
- Working Capital Trends: Review the negative operating cash flow of $25.5 million for the six-month period, driven largely by the $90 million Affymetrix settlement payment and increased inventory buildup.
- Stock-Based Compensation: Note the significant increase in non-cash stock-based compensation ($23.1 million for the six months ended June 29, 2008) and its impact on future expense recognition.
- Avantome Integration: Assess the strategic value and financial impact of the subsequent Avantome acquisition on future R&D and sequencing capabilities.